Abstract

Human galectins have distinct and overlapping biological roles in immunological homeostasis. However, the underlying differences among galectins in glycan binding specificity regulating these functions are unclear. Galectin-8 (Gal-8), a tandem repeat galectin, has two distinct carbohydrate recognition domains (CRDs) that may cross-link cell surface counter receptors. Here we report that each Gal-8 CRD has differential glycan binding specificity and that cell signaling activity resides in the C-terminal CRD. Full-length Gal-8 and recombinant individual domains (Gal-8N and Gal-8C) bound to human HL60 cells, but only full-length Gal-8 signaled phosphatidylserine (PS) exposure in cells, which occurred independently of apoptosis. Although desialylation of cells did not alter Gal-8 binding, it enhanced cellular sensitivity to Gal-8-induced PS exposure. By contrast, HL60 cell desialylation increased binding by Gal-8C but reduced Gal-8N binding. Enzymatic reduction in surface poly-N-acetyllactosamine (polyLacNAc) glycans in HL60 cells reduced cell surface binding by Gal-8C but did not alter Gal-8N binding. Cross-linking and light scattering studies showed that Gal-8 is dimeric, and studies on individual subunits indicate that dimerization occurs through the Gal-8N domain. Mutations of individual domains within full-length Gal-8 showed that signaling activity toward HL60 cells resides in the C-terminal domain. In glycan microarray analyses, each CRD of Gal-8 showed different binding, with Gal-8N recognizing sulfated and sialylated glycans and Gal-8C recognizing blood group antigens and polyLacNAc glycans. These results demonstrate that Gal-8 dimerization promotes functional bivalency of each CRD, which allows Gal-8 to signal PS exposure in leukocytes entirely through C-terminal domain recognition of polyLacNAc glycans.

Highlights

  • Members, such as FasL and tumor necrosis factor-␣, induce apoptotic cell death in target cells [3,4,5], which favors immunologically silent removal [7]

  • Gal-8 Induces PS Exposure in HL60 Cells—To elucidate the binding specificity of Gal-8 toward leukocyte cell surface glycans, we first examined the ability of Gal-8 to induce PS exposure in HL60 cells

  • Gal-8 induced PS exposure in a dose-dependent manner (Fig. 1F) with similar kinetics as observed with other galectins [2, 40] (Fig. 1G). This PS exposure occurred independently of apoptosis, because there was no enhancement of cell or DNA fragmentation (Fig. 2, A–E), and cell viability was unaltered by Gal-8 treatment over 72 h (Fig. 2F)

Read more

Summary

The abbreviations used are

Gal-3, human galectin-3; Gal-8, human galectin-8; Gal-8N, N-terminal domain of Gal-8; Gal-8C, C-terminal domain of Gal-8; Gal-8NM, R69H mutant of Gal-8; Gal-8CM, R233H mutant of Gal-8; TDG, thiodigalactoside (␤-D-galactopyranosyl-1-thio-␤-D-galactopyranoside); 2-ME, 2-mercaptoethanol; LacNAc, N-acetyllactosamine (Gal␤1– 4GlcNAc); polyLacNAc, poly-N-acetyllactosamine (-3Gal␤1– 4GlcNAc␤1-)n; CRD, carbohydrate recognition domain; PI, propidium iodide; PS, phosphatidylserine; RCA, Ricinus communis agglutinin; LEA, Lycopersicon esculentum agglutinin; BS3, bis(sulfo-succinimidyl) suberate. Galectin-8 is a tandem repeat galectin of ϳ36 kDa with two carbohydrate-recognition domains (CRDs). It is expressed in a wide variety of organs and cells, including endothelial cells and human thymocytes [26, 27], and its expression is up-regulated in several cancers [28]. Each domain recognizes cell surface glycans, only the C-terminal domain of Gal-8 recognizes polyLacNAc cell surface glycans (-3Gal␤1– 4GlcNAc␤1-)n and induces preaparesis in HL60 cells. These results challenge the current paradigm concerning the mechanisms of tandem repeat galectin signaling and strongly suggest complex biological roles for this subfamily of tandem repeat galectins

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call